Luca Lucente

Medical Oncology Resident in training at @SanMartino_Ge 🇮🇹 @UniGenova, Focused on #LungCancer 🫁 and #NeuroOncology 🧠

[Marco Tagliamento @M_Tagliamento]

Glad to have contributed to the @JTOonline 20th anniversary series!
Immunotherapy has reshaped the treatment of #LungCancer. We’ve looked back at how we got here and to what comes next.

@BarlizW @KamyaSankar @KarenReckamp
@IASLC @CedarsSinai @UniGenova

https://t.co/W1PqjiPl4R

[Luca Lucente @Dr_LucaLucente]

Grateful to @CarloGenova5 @LucreziaBarc @beatricerampol Clara Lidia Filipazzi Simona Coco Margherita Puppo Silvia Marconi Sara Santamaria @M_Tagliamento @giovann64534267 Chiara Dellepiane Elisa Bennicelli Giulia Barletta Linda Zinoli
for your guidance, collaboration and support💪

[Luca Lucente @Dr_LucaLucente]

Our review on #EGFR-targeted therapies in #NSCLC is out now🎉open access on @tandfonline📖🔗https://t.co/a2lblOrneu
Exploring the evolving landscape from #osimertinib to combination strategies (FLAURA2, MARIPOSA), ADCs and #ctDNA guided strategies. #LungCancer #OncTwitter

[Marco Tagliamento @M_Tagliamento]

“The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology”
Check our comprehensive review, including the management in clinical practice

Led by Mégane Tanguay
@JB_Micol @Elsa2Bernard @BenjaminBesseMD
@GustaveRoussy @UniGenova

https://t.co/2ymKKdKJt9

[Rami Manochakian MD, FASCO @RManochakian]

🔥🚨@OncoAlert Hot off the press

❇️The long-awaited #GoodNews:

@US_FDA approves:

⭐️#Subcutaneous #Amivantamab for:

🔷Advanced #EGFRm non-small-cell #LungCancer (in combination with #Lazertinib) based on the #PALOMA3 Trial which showed:

��Significant ⬇️#Toxicity
✅Noninferior #PK
✅Similar #Efficacy

👇🏻
https://t.co/6OHAqIxx8Q

[Lombardi Giuseppe @DrLombardiGiu]

📢 Proud to contribute to the international STELLAR trial, out in JCO.
In recurrent IDHmut grade 3 astrocytoma, eflornithine + lomustine showed:
• PFS doubled (15.8 vs 7.2ms)
• OS significantly improved (34.9 vs 23.5ms)
https://t.co/3bAAbS9D4G
@NeuroOnc
@EANOassociation

[Luca Lucente @Dr_LucaLucente]

What an amazing experience at the @myESMO Preceptorship on #SCLC in 📍Zurich!
Grateful for the chance to learn, share, and connect with brilliant oncology professionals from across E. An inspiring step in my training journey! 🫁
#ESMO #Oncology #LungCancer
https://t.co/72GUzBr8OI

[Luca Arecco, MD @Lucarecco]

Another insightful talk by great @BlondeauxEva at #ESMO25!

While most RCTs report discontinuation rates, post-study treatments are rarely documented.
Different attrition rates across arms can bias long-term outcomes (including OS!!)

➡️ Better reporting essential! @OncoAlert

[Luca Lucente @Dr_LucaLucente]

Congrats to my mentor @giovann64534267 and my friend & colleague @LucreziaBarc on their work! Big shoutout to all the other colleagues from @SanMartino_Ge who contributed 👏👏👏
https://t.co/tSc1x8nBSW
🫁#NSCLC #LungCancer #neoadjuvant #adjuvant #perioperative #immunotherapy

[Marco Tagliamento @M_Tagliamento]

Huge meta-analytic work led by @giovann64534267 exploring the efficacy of neoadjuvant and adjuvant IO in resectable NSCLC in different disease subgroups. Happy to have contributed

Link: https://t.co/hpqe3zYrEV

@ESMO_Open @myESMO @IASLC @SanMartino_Ge @UniGenova @OncoAlert

[Lucia Del Mastro @delmastro_lucia]

Tra i miei obiettivi come candidata presidente @AIOMtweet: rafforzare la collaborazione con le Università.

Serve ampliare le reti formative delle scuole di specializzazione e aumentare i posti in oncologia per rispondere al crescente fabbisogno di cura e ricerca.

[FJ ⭐️⭐️+⭐️ @pistoto2017]

Great news for the #sclc patients. #Imforte = #Lurbinectedin + #Atezolizumab is included in the NCCN guidelines for 1L Maintenance treatment. Great step for the patients!!! #pharmamar #zepzelca #tecentriq @PhrmMar @JazzPharma #lungcancer

[Alessio Cortellini @ACortelliniMD]

Big #WCLC2025 week for 1L EGFR+ NSCLC 🚀
OS+ for MARIPOSA (#NEJM) & FLAURA2 (@dplanchard ) ✅ @IASLC
3 clear frameworks: Osi mono (still key for frail pts), FLAURA2, MARIPOSA (w/ subq ami q4w → better logistics & ↓IRR)
Not a race, new agents (IZA-BREN?) will raise the bar eventually🤭
Now it’s about shared treatment goals with patients, cause more option means more personalization, weighing efficacy, priorities, logistics, safety, expectations.. @EGFRResisters @EgfrUk

[EORTC @EORTC]

📢 Virginia Delucchi presented her poster at #ISCB46 in Basel!

Her study reviewed 500+ RCTs of solid tumours and found that while discontinuation is widely reported, post-treatment data often isn’t. Potentially leading to misinterpretation of treatment effects.

#CancerCare

[ESMO - Eur. Oncology @myESMO]

📣 Updated ESMO #ClinicalPracticeGuideline on early & locally advanced #NSCLC: new systemic treatments, innovative strategies & advanced therapeutic options to personalise #PatientCare & improve outcomes.

🔗 https://t.co/BPNEfzhl5e

#LungCancer #SystemicTherapy #Oncology #CancerTreatment

[Lucia Del Mastro @delmastro_lucia]

Le azioni concrete per sostenere i giovani oncologi:
- iscrizione ridotta per under 40
- più spazio in attività e congressi
- favorire mobilità
- nuovi strumenti formativi
#Oncologia
#AIOMGiovani
#RicercaOncologica
#INSIEME

[International Society of Liquid Biopsy @isliquidbiopsy]

🚨 #ASCO25 Liquid Biopsy Highlights
Liquid biopsy is entering clinical practice 🚀
🔹 Plasma-guided chemo in NSCLC
🔹 ctDNA-driven therapy switch in HR+/HER2− BC
🔹 ctDNA-negativity ➡️ less axillary surgery?
🔹 Post-op ctDNA = strong prognostic tool in CRC & MIBC
🔹 Multi-omics & Pap-derived cfDNA → future of early detection & risk stratification

📉 But challenges remain: assay heterogeneity, discordant results, and standardization needs.
🧪 Full editorial from #ISLB Young Committee in @jlb_islb
🔗https://t.co/UyC2ZGJqdz

@ChristianRolfo @ElJanLe @DrYukselUrun @UmbertoMalapel1 @drgandara @MJOSESERRANO19 @RobertoBoreaMD @ReduzziCarol @AngeloDiPa

[Biagio Ricciuti, MD, PhD @BRicciutiMD]

@DiFedericoMD @TumorBoardTues @BiagioRicciutMD @IntegrityCE @alessi_joao @pecci_federica1 @RobertoFerrara_ @NarjustFlorezMD @MarceloCorassa @DrMarkAwad @StephenVLiu @BalazsHalmosMD @PTarantinoMD @EdoardoGarbo @FSkoulidis @FawziAbuRous @ADesaiMD @thenasheffect @ACortelliniMD @ChristianRolfo @ABarsouk @Alfdoc2 @lungoncdoc @JackWestMD 9/20 | #TumorBoardTuesday

So—how do we treat STK11/KEAP1-mutant cases?

👉 Evidence suggests intensified approaches, such as chemo + PD-(L)1 ± CTLA-4 blockade, might be beneficial in certain circumstances (e.g., PD-L1<1%; STK11 & KEAP1 co-mutations or w/ KRAS. @marinagarassino

[Rami Manochakian MD, FASCO @RManochakian]

🔥🚨Hot Off the Press #BigNews

Press Release by @AstraZeneca

⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows:

✅Statistically Significant & Clinically Meaningful Improvement in #OverallSurvival (⬆️#OS)

👇🏻
https://t.co/wzrFF2Ghc3

[IASLC @IASLC]

Datopotamab deruxtecan is now FDA approved for EGFR-mutant #NSCLC after prior EGFR & platinum therapy.

In this episode of #LungCancerConsidered, @N@NarjustFlorezMD and @sands_jacob break down the data and clinical implications of this exciting development.

🎧 https://t.co/M1Ld9fZSqQ

[Roberto Ferrara @RobertoFerrara_]

🌓Yin&Yang Masterclass 2025 1st edition comes to an end. Huge thanks to all young and early-career investigators for stepping up, and to the stellar faculty for guiding them with passion and vision. Next stop: Paris 2026 🇨🇵 Stay tuned! #YinYang2025
@mihaela_aldea @BRicciutiMD